Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent ...

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK ...

Dear Dr. Roach: Can you please give more insight into carcinoid syndrome? In particular, I'd like to know its symptoms and how it gets diagnosed and treated? What kind of a doctor would one see with ...

Somatostatin analogs (SSAs) like octreotide LAR and lanreotide are essential in managing NETs. Standard practice involves ...

Shubham Pant, MD: The first thing people say when people hear “tumor” is, “Oh my God, I’m going to die, this is a tumor.” But tell me, as a doctor who treats neuroendocrine tumors, there can be ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. For over two decades, my husband Lance – unknowingly, until the very end – ...

As Crinetics prepares to make a tilt for FDA approval in a rare growth disorder later this year, a topline readout from a phase 2 study suggests the same drug also has the potential to treat symptoms ...

Xermelo (telotristat ethyl) was approved by the Food and Drug Administration (FDA) to treat diarrhea in patients with carcinoid syndrome. The Food and Drug Administration (FDA) approved Xermelo ...

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) ...

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization ...